Clinical utility of repeated rebiopsy for EGFR T790M mutation detection in non-small cell lung cancer

In cases where rebiopsy fails to find the epidermal growth factor receptor (EGFR) T790M mutation, the criteria for selecting patients for repeated rebiopsy remains unclear. This study aimed to assess the impact of repeated rebiopsy on T790M mutation detection in non-small cell lung cancer (NSCLC) pa...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2024-08, Vol.14, p.1452947
Main Authors: Lee, Eun Hye, Kwak, Se Hyun, Kim, Kyeong Yeon, Kim, Chi Young, Lee, Sang Hoon, Heo, Seok-Jae, Chang, Yoon Soo, Kim, Eun Young
Format: Article
Language:English
Subjects:
EGFR
lung cancer
Oncology
rebiopsy
repeated biopsy
T790M
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In cases where rebiopsy fails to find the epidermal growth factor receptor (EGFR) T790M mutation, the criteria for selecting patients for repeated rebiopsy remains unclear. This study aimed to assess the impact of repeated rebiopsy on T790M mutation detection in non-small cell lung cancer (NSCLC) patients. Patients with advanced EGFR-mutated NSCLC between January 2018 and December 2021 at three-referral hospitals in South Korea underwent retrospective review. Of 682 patients who had rebiopsy after disease progression, T790M mutation status was assessed in plasma circulating tumor DNA (ctDNA) and/or tumor tissues. The overall T790M positivity rate increased from 40.8% after the first rebiopsy to 52.9% following multiple rebiopsies in the entire study population. Longer duration of initial EGFR TKI use (OR 1.792, ≥8 months vs.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2024.1452947